Similarly, in mouse xenograft models of KMT2Ar AML with concurrent FLT3 mutations, combining MIs and an FLT3 inhibitor resulted in better survival outcomes than monotherapy with either agent. The gene discussed is FLT3; the disease is acute myeloid leukemia.